Candriam S.C.A. Syros Pharmaceuticals, Inc. Transaction History

Candriam S.C.A.

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 03, 2022	SELL	$0.69 - $1.21 $403,147 - $706,969	-584,272 Closed	0 $0
Q2 2021 Jul 20, 2021	BUY	$5.01 - $7.48 $2.93 Million - $4.37 Million	584,272 New	584,272 $3.18 Million
Q4 2019 Jan 21, 2020	SELL	$4.52 - $10.1 $763,879 - $1.71 Million	-169,000 Closed	0 $0
Q2 2019 Aug 01, 2019	SELL	$5.5 - $9.75 $192,500 - $341,250	-35,000 Reduced 17.16%	169,000 $1.56 Million
Q1 2018 May 09, 2018	SELL	$9.47 - $12.98 $56,820 - $77,880	-6,000 Reduced 2.86%	204,000 $2.65 Million
Q4 2017 Feb 07, 2018	BUY	$8.45 - $17.48 $760,499 - $1.57 Million	90,000 Added 75.0%	210,000 $2.04 Million
Q3 2017 Nov 03, 2017	BUY	$13.52 - $23.75 $1.62 Million - $2.85 Million	120,000	120,000 $1.77 Million

Ticker SYRS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 20,236,200
Market Cap $43.1M
Description
Syros Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development of treatments for cancer and monogenic diseases, and building a pipeline of gene control medicines. The company's lead product candidates are Tamibarotene, a selective retinoic acid receptor alpha agonist, which is in Phase III clinical trial for genomically def...

Get notified when there are updates to the investment portfolio of Candriam S.C.A., based on Form 13F filings with the SEC.

Stay updated on Candriam S.C.A. with notifications on news.